Regenerative Medicine Recommendations

RepliCel Life Sciences Inc.

Douglas Loe, Echelon Wealth Partners (9/6/18) "Liquidity metrics in Q2/18 indicated RP exited with cash of $48.8K."

Douglas Loe, Echelon Wealth Partners (7/12/18) "RP signed on its licensing and codevelopment deal with YOFOTO."

Douglas Loe, Echelon Wealth Partners (1/16/18) "RP consummated a new strategic alliance with China-based Yofoto."

The Life Sciences Report Interview with Colin Lee Novick (10/4/17) RP's Phase 1/2a trial for tendon repair in chronic Achilles tendinosis met its goal and established a complete safety profile at six months that showed no serious adverse events."

Douglas Loe, Echelon Wealth Partners (9/13/17) "RP is currently in discussions with potential partnerships focused not just on the firm's injector, but also on its regenerative medicine therapies."

Douglas Loe, Echelon Wealth Partners (8/16/17) "RP announced its participation in the ThawSTAR Early Adopter Program."

Regeneus Ltd.

Dennis Hulme, Edison Investment Research (5/31/17) "RGS' Phase I Progenza safety trial met its primary endpoint."

Dennis Hulme, Edison Investment Research (5/18/17) "RGS' strategy is to partner its product opportunities for development and commercialisation, allowing it to focus on early-stage product development."

Dennis Hulme, Edison Investment Research (4/24/17) "RGS' strategy is to partner its product opportunities for development and commercialization, allowing it to focus on early-stage product development."

RepliCel Life Sciences Inc.

BioTuesdays Publishing Co. (4/4/17) "RP reported statistically and clinically significant positive data from an interim analysis of its Phase I study evaluating RCS-01 for the treatment of aging and sun-damaged skin."

Etienne Moshevich, Alphastox.com (4/4/17) "RP is finally in a position to drive substantial growth for shareholders by advancing all three clinical programs as well as continuing to build out their medical device."

Douglas Loe, Echelon Wealth Partners (4/4/17) "Clear evidence that RP's RCS-01 up-regulates biochemical pathways that are known to be relevant to skin rejuvenation as study design intended."

SmallCap Network (4/4/17) "RP announced statistically and clinically significant positive data from the interim analysis of its phase I study evaluating RCS-01 for the treatment of aging and sun-damaged skin, and the markets are loving the news."

Zacks Small Cap Research (4/3/17) "The results from RP's Phase 1 trial show that RCH-01 has a very clean safety profile."

Douglas Loe, Echelon Wealth Partners (3/28/17) "We believe our valuation is conservative when considering how solidly RP has demonstrated functional improvement in at least two cell therapy markets."

James West, Midas Letter (3/27/17) "RP recently completed a Phase 1 Clinical Trial that has moved the company that much closer to realizing that goal, and from an investor perspective, the news could not be better."

Regeneus Ltd.

Dennis Hulme, Edison Investment Research (3/23/17) "In addition to RGS' deal for Progenza in Japan, it has partnered with a top-5 global animal health company for development of CryoShot Canine."

RepliCel Life Sciences Inc.

Shane Matte, BioTuesdays (3/14/17) "RP has successfully completed its first-in-human clinical study of the company's autologous cell therapy for the treatment of androgenetic alopecia."

Douglas Loe, Echelon Wealth Partners (3/14/17) "We now have two-year data to show that RP's RCH-01 had a measurable impact on hair density in a sizable proportion of patients."

Inovio Pharmaceuticals Inc.

Zacks Equity Research (3/6/17) "Investor focus should remain on pipeline updates as many such events are lined up along with the INO's plans related to the development of its Ebola and Zika vaccines."

RepliCel Life Sciences Inc.

James Brumley, SmallCap Network (2/28/17) "RP is moving more rapidly than perhaps most shareholders have expected."

Regeneus Ltd.

Dennis Hulme, Edison Investment Research (2/16/17) "RGS will seek wider applications of Progenza beyond osteoarthritis."

RepliCel Life Sciences Inc.

George Mack, BioDecade (2/16/17) "RP’s current minimalist market cap of under $US20 million and the fact that movement of these clinical studies into phase 2 and phase 3 could mean a very significant increase in share price."

Alphastox (2/12/17) "RP is sure to be one of the most exciting stories of 2017."

BioTuesdays (2/9/17) "RP announced the granting of two patents in Europe."

The Life Sciences Report Interview with Colin Lee Novick (2/1/17) "I would keep my eyes peeled on RP and Shiseido in the coming months for indications as to when the male pattern baldness therapy will become available in Japan."

Regeneus Ltd.

The Life Sciences Report Interview with Colin Lee Novick (2/1/17) "The RGS-Asahi Glass deal is nicely designed."

Dennis Hulme, Edison Investment Research (1/27/17) "Our valuation of RGS increases with the AGC cash and larger addressable market in Japan partly offset by longer timelines and revised assumptions for CryoShot and Kvax."

RepliCel Life Sciences Inc.

Zacks Equity Research (1/24/17) "One company that looks very well-positioned to benefit from regenerative medicine's rising tide is RP."

Zacks Equity Research (1/24/17) "The recent uptick in the stock is just the beginning for RP."

Alphastox.com (1/22/17) "We've been wildly successful with a couple of our biotech picks, including RepliCel Life Sciences Inc., which is up over 250% in just three months."

Regeneus Ltd.

Dennis Hulme, Edison Investment Research (12/8/16) "Cancer immunotherapy, including cancer vaccines such as RGS' RGSH4K, is a biotech hotspot."

Dennis Hulme, Edison Investment Research (11/17/16) "RGS has firmed up its strategy to partner its product opportunities for development and commercialization, allowing it to focus on early-stage product development."

RepliCel Life Sciences Inc.

Douglas Loe, Echelon Wealth Partners (11/2/16)

Regeneus Ltd.

Maxim Jacobs, Edison Investment Research (10/20/16) "RGS has firmed up its strategy to partner its product opportunities for development and commercialization, allowing it to focus on early-stage product development."

RepliCel Life Sciences Inc.

Douglas Loe, Echelon Wealth Partners (9/28/16)

Regeneus Ltd.

Dennis Hulme, Edison Investment Research (9/14/16) "RGS anticipates entering a binding arrangement with a manufacturing and commercialisation partner."

Dennis Hulme, Edison Investment Research (8/18/16) "Cancer immunotherapy, including cancer vaccines such as RGS' RGSH4K, is a biotech hotspot."

Dennis Hulme, Edison Investment Research (6/23/16) "RGS aims to finalize manufacturing and clinical development partnerships in Japan in Q2/16."

Dennis Hulme, Edison Investment Research (5/19/16) "RGS positive safety review augurs well for the company's plan to secure a manufacturing and commercial partner for Progenza in Japan."

The Life Sciences Report Interview with Dennis Hulme (5/11/16) "There is strong potential RGS will strike a commercialization deal in Japan sometime this year; that's going to be the key driver."

Resverlogix Corp.

Marcel Wijma, Van Leeuwenhoeck Research (5/11/16) "With a successful Phase III trial and considering the market potential for RVX-208, a very significant upside potential for RVX-208 and RVX is attainable."

Athersys Inc.

Jason Kolbert, Maxim Group (5/6/16) "There is unusually strong alignment and interest by both ATHX and Healios to expand MultiStem to other indications for Japan."

Wall Street Titan, Seeking Alpha (4/27/16) "With its new partner, Healios, ATHX has set itself up for an exciting future."

Mesoblast Ltd.

Katherine Genis, Edison Investment Research (3/24/16) "Phase 3 study data will support approval of MESO's MPC-150-IM."

Regeneus Ltd.

Dennis Hulme, Edison Investment Research (3/24/16) "RGS aims to finalize partnerships in Japan in Q2/16."

Athersys Inc.

Maxim Jacobs, Edison Investment Research (3/24/16) "A Phase 2 trial with ATHX's MultiStem in AMI is underway."

Mesoblast Ltd.

Jason Kolbert, Maxim Group (3/17/16) "The rebound in MESO's valuation is justified."

Athersys Inc.

Jason Kolbert, Maxim Group (3/11/16) "A positive outcome for ATHX's MultiStem in stroke is probable."

Maxim Jacobs, Edison Investment Research (3/4/16) "ATHX's deal with Healios increases milestone payments and royalties."

Cynata Therapeutics Ltd.

Dr. Ram Selvaraju, Rodman & Renshaw (3/4/16) "CYP signed an agreement with Regience to co-commercialize Cymerus."

RepliCel Life Sciences Inc.

The Life Sciences Report Interview with Eden Rahim (3/2/16) "RP management has secured a partnership with Shiseido Company in Japan to fund its alopecia trials."

Asterias Biotherapeutics Inc.

Henry McCusker, RegMed Investors (2/25/16) "The FDA agreed with AST's plan for registration of AST-VAC1."

Mesoblast Ltd.

Henry McCusker, RegMed Investors (2/25/16) "A MESO licensee launched Temcell in Japan for treatment of aGVHD."

Regeneus Ltd.

Dennis Hulme, Edison Investment Research (2/25/16) "RGS is developing and commercializing its adipose-derived mesenchymal stem cell technology for musculoskeletal conditions in animals and humans."

Athersys Inc.

Maxim Jacobs, Edison Investment Research (2/25/16) "ATHX has a Phase 2 trial with MultiStem in acute myocardial infarction underway with data expected in H2/16"

Mesoblast Ltd.

Kevin DeGeeter, Ladenburg Thalmann (2/23/16) "New results increased our confidence in MESO's Phase 3 aGVHD study."

Jason Kolbert, Maxim Group (2/22/16) "MESO's MSC-100-IV in aGVHD showed clinically meaningful responses."

Regeneus Ltd.

The Life Sciences Report Interview with Marcel Wijma (2/17/16) "RGS could be Australia's second success story in the stem cell industry."

Athersys Inc.

Jason Kolbert, Maxim Group (2/17/16) "ATHX's follow-up data showed patients receiving MultiStem continued to improve and had a statistically significant higher rate of 'Excellent Outcome.'"

Mesoblast Ltd.

Jason Kolbert, Maxim Group (2/16/16) "Trial data on MSB's MPC-300 IV show no risk but clearly activity."

Athersys Inc.

The Life Sciences Interview with Ram Selvaraju (2/10/16) "ATHX is getting a $15M upfront cash payment as part of its agreement with Tokyo-based big pharma Healios."

Cynata Therapeutics Ltd.

The Life Sciences Interview with Ram Selvaraju (2/10/16) "CYP has the only truly sustainable production platform for MSCs."

Regeneus Ltd.

Proactive Investors (2/10/16) "RGS's Progenza has enhanced its potential for commercialization after an encouraging review of safety data from an oversight committee."

Cynata Therapeutics Ltd.

Dr. Ram Selvaraju, Rodman & Renshaw (1/28/16) "CYP received favorable clinical testing advice from the MHRA."

Mesoblast Ltd.

Katherine Genis, Edison Investment Research (1/25/16) "MSB continues to make good pipeline progress."

RepliCel Life Sciences Inc.

The Life Sciences Report Interview with Alan Leong (1/20/16) "RP had successful proof of concept with RCH-01 with restoring hair."

BrainStorm Cell Therapeutics Inc.

Jason Kolbert, Maxim Group (1/19/16) "JAMA Neurology published findings of ALS trials with BCLI's NurOwn."

Athersys Inc.

Jason Kolbert, Maxim Group (1/13/16) "Data suggest ATHX's MultiStem could have benefit post hypoxic ischemia."

Mesoblast Ltd.

Jason Kolbert, Maxim Group (1/11/16) "Revisions to MSB's ongoing Phase 3 program are very positive."

BrainStorm Cell Therapeutics Inc.

Jason Kolbert, Maxim Group (1/11/16) "BCLI and Hadassah Medical agreed to a Phase 2 AML trial collaboration."

Athersys Inc.

Jason Kolbert, Maxim Group (1/8/16) "ATHX's partnership and licensing with Healios is very positive news."

Henry McCusker, RegMed Investors (1/8/16) "ATHX has partnered to develop cell therapy treatments in Japan."

Mesoblast Ltd.

Jason Kolbert, Maxim Group (12/31/15) "In 2016, we will be closely watching MSB's DDD (back pain) trial."

Kevin DeGeeter, Ladenburg Thalmann (12/17/15) "We expect MSB, following restructuring, to be funded through fiscal Q4/17."

Asterias Biotherapeutics Inc.

The Life Sciences Report Interview with George Zavoico (12/16/15) "Durable survival was reported in AST's small Phase 2 trial in acute myeloid leukemia."

Mesoblast Ltd.

Kevin DeGeeter, Ladenburg Thalmann (12/8/15) "Professor Joanne Kurtzberg discussed aGHVD treatments including MSB's."

Cynata Therapeutics Ltd.

Dr. Ram Selvaraju, Rodman & Renshaw (12/7/15) "We initiate coverage of CYP with a Buy rating."

Mesoblast Ltd.

Kevin DeGeeter, Ladenburg Thalmann (12/4/15) "MSB's Phase 3 study in GvHD is likely to meet its primary endpoint."

Athersys Inc.

The Life Sciences Report Interview with Jason Kolbert (12/2/15) "ATHX's MultiStem is going to prove viable, and will change the paradigm for treating stroke."